Sendai virus for gene therapy and vaccination.
Sendai virus for gene therapy and vaccination.
复制标题
仙台病毒用于基因治疗和疫苗接种。
DOI：
--
复制
发表时间：
2005
影响因子：
--
通讯作者：
E. Alton
中科院分区：
文献类型：
--
作者：
U. Griesenbach;M. Inoue;M. Hasegawa;E. Alton
仙台病毒（SeV），也称为日本血凝病毒（HVJ），是一种负链RNA病毒，是副粘病毒科的一员。SeV增强脂质囊泡和细胞膜融合的能力在20世纪80年代初被发现，并以hvj脂质体的形式被利用。最近，反向遗传学的进展已经允许构建一类新的具有细胞质表达的RNA载体，即非传染性重组SeV。广泛的临床前研究表明，该载体具有用于呼吸道、脑部以及缺血性疾病和肿瘤的治疗潜力。此外，还探索了SeV载体用于疫苗接种的潜力。本文回顾了2004年1月以来SeV用于基因治疗和疫苗接种的数据，并讨论了SeV病媒学的最新进展。
Sendai virus (SeV), also known as hemagglutinating virus of Japan (HVJ), is a negative-strand RNA virus and a member of the paramyxovirus family. The capacity of SeV to enhance fusion of lipid vesicles and cell membranes was recognized in the early 1980s, and has since been utilized in the form of HVJ-liposomes. More recently, advances in reverse genetics have allowed the construction of a new class of RNA vector with cytoplasmic expression, namely non-transmissible recombinant SeV. Extensive preclinical studies have shown the therapeutic potential of this vector for use in airways, brain and for ischemic diseases and tumors. In addition, the potential of SeV vector for vaccination has been explored. Data on the use of SeV for gene therapy and vaccination since January 2004 are reviewed and recent improvements in SeV vectorology are discussed.